Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)

NCT ID: NCT04705844

Last Updated: 2022-03-03

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-09-30
• Study Completion Date: 2022-09-30

Brief Summary

Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19

Conditions

Mild to Moderate COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Adalimumab

single dose of adalimumab(160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen

Group Type: EXPERIMENTAL

Adalimumab

Intervention Type: DRUG

adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)

Placebo

single dose of placebo (administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)

Interventions

Adalimumab

adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)

Intervention Type: DRUG

Placebo

placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)

Intervention Type: DRUG

Other Intervention Names

Humira

Eligibility Criteria

Inclusion Criteria

• Subject (or their legally authorized representative) is willing and able to provide written informed consent prior to performing study procedures.
• Understands and agrees to comply with planned study procedures.
• Male or non-pregnant female adult ≥60 and ≤ 80years of age OR male or non-pregnant female adult ≥40 and ≤80 years, with one or more of the following risk factors (asthma, diabetes, hypertension, obesity [body mass index >30], cardiovascular disease).
• Has a laboratory-confirmed SARS-CoV-2 infection as determined by FDA-approved rapid diagnostic (e.g., polymerase chain reaction [PCR]) assay within the preceding 7 days (168 hours).
• Has at least 2 COVID-19 related symptoms on the 14-question COVID-19 questionnaire.
• Has peripheral capillary oxygen saturation (SpO2) >93% by pulse oximetry.
• C-reactive protein (CRP) >50 mg/L or lymphopenia (<1.5×109/L) or neutrophilia (>7.5×109/L).
• Agrees to the collection of blood and urine samples, nasal swabs , and non-invasive oxygen monitoring (via pulse oximeter) per protocol.
• Willing to receive 4 injections at separate sites on the thigh or abdomen.
• Women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception (not including hormonal contraception) from the time of screening through Day 29 following randomization.
• Agrees to not participate in any other clinical trial (both pharmacologic and other types of interventions) through Day 29 following randomization

Exclusion Criteria

• Received or contemplating any COVID-19 vaccine or participated in a COVID-19 vaccine trial.
• Subject is considered to be in their last few weeks of life prior to this acute illness.
• History of pulmonary alveolar proteinosis.
• History of hematopoietic stem cell transplant or solid organ transplant.
• Previous malignancy and lymphoproliferative disorders (within the last 5 years) with the exception of stable prostate cancer and basal cell carcinoma.
• Chronic obstructive pulmonary disease on long-term oxygen therapy - subjects with forced expiratory volume in 1 second known to be <50% will also be excluded.
• Demyelinating disease.
• Known history of hepatitis B, HIV, or untreated hepatitis C infection
• Severe hepatic impairment or known cirrhosis - Child-Pugh score B or higher.
• Acute kidney injury Stage 3
• Tuberculosis or other severe infections such as (non-COVID-19) sepsis, abscesses, fungal superinfection and opportunistic infections requiring treatment.
• Positive Quantiferon Gold test at screening
• Moderate or severe heart failure (New York Heart Association Class III/IV).
• Treatment with monoclonal antibodies targeting cytokines (e.g., TNF inhibitors [adalimumab, infliximab, etanercept, golimumab, certolizumab]; anti-IL-1 [e.g., anakinra, canakinumab]; anti-IL-6 or anti-IL-6r [e.g., tocilizumab, sarilumab, sitlukimab]; or T-cells [e.g., abatacept]) in past 90 days (5 half-lives of the drug), or contemplating treatment with any of these agents during the trial period.
• Treatment with monoclonal antibodies targeting B-cells (e.g., rituximab, and including any targeting multiple cell lines including B-cells) in the 3 months prior to screening.
• Received GM-CSF agents (e.g., sargramostim) within 2 months prior to screening.
• Treatment with other immunosuppressants in the 4 weeks prior to screening and in the judgment of the Investigator, the risk of immunosuppression with adalimumab is larger than the risk of COVID-19.
• Treatment with small molecule tyrosine kinase inhibitors (e.g., baricitinib, ibrutinib, acalabrutinib, imatinib, gefitinib), in the 4 weeks prior to screening.
• Received or contemplating receipt of any live vaccine or any investigational vaccine in the 4 weeks prior to screening.
• Current participation or previous participation in any other clinical trial within 30 days prior to randomization.
• Subjects with known hypersensitivity to adalimumab or excipients of adalimumab as stated in the label.
• Pregnant female
• Lactating female
• Women of childbearing potential who do not agree to either abstinence or use of at least one primary form of contraception (not including hormonal contraception) from the time of screening through Day 29 following randomization.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pharm-Olam, LLC

INDUSTRY

Sponsor Role: collaborator

Chemical, Biological, Radiological, and Nuclear Medical

UNKNOWN

Sponsor Role: collaborator

Alachua Government Services, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

A21-070

Identifier Type: -

Identifier Source: org_study_id